Comparison of the Effects of Prednisolon, Danazol and Testosteron Propionat Therapy in Dogs with Immune Mediated Hemolytic Anemia and Thrombocytopenia

Yıl 2010, Cilt: 29 Sayı: 2, 57 - 63, 01.06.2010

Sezgin Şentürk Mutlu Temizel Hüseyin Cihan Nilüfer Aytuğ

https://izlik.org/JA55FD27JD

Öz

Anahtar Kelimeler

-

Comparison of the Effects of Prednisolon, Danazol and Testosteron Propionat Therapy in Dogs with Immune Mediated Hemolytic Anemia and Thrombocytopenia

https://izlik.org/JA55FD27JD

Öz

Bu çalışma Prednisolon, Danazol ve Testosteron propionate’ın İmmun ilişkili anemi (İHA) ve immun ilişkili trombositopenili (İT) 45 köpeğin tedavisindeki etkinliğinin belirlenmesi ve karşılatırılması amacıyla yapıldı. Bütün köpekler 2003–2007 yılları arasında Uludağ Üniversitesi Veteriner Fakültesi İç Hastalıkları Kliniğiinde İHA ve İT taısı konan köpekler arasından seçildi. Bütün köpeklere ait klinik, hematolojik ve biyokimyasal muayeneler 3 hafta boyunca yapıldı. Çalışmada kullanılan köpekler her biri 15 köpekten oluşan 3 gruba ayrıldı; 1. Gruba immunsupresif dozajda prednisolone uygulandı. 2. Gruba Danazol ve 3. Gruba testoterone propionate uygulandı. Köpeklerde ilk muayene sonuçları arasında solgun mukoz membranlar, ikterus, hemoglobinüri, peteşi, ekimoz, melena ve epistaksis saptandı. Hemoglobin ve hematkrit düzeyleri tedavi sonunda 3. grup hayvanlara göre 1. ve 2. gruptaki hayvanlarda istatistiki olarak daha yüksek olarak saptandı (P=0.05) Trombosit sayısı tedavinin sonunda 1. ve 2. Gruptaki hayvanlarda normal sınırlar içindeydi. Sonuç olarak, prednisolone ve danazol uygulamaları tedavide etkili olurken, testosterone propionate tedavisde etkili olmadığı belirlenmiştir

Anahtar Kelimeler

Anemi , platelet , eritrosit , kortikosteroid , androjen

Kaynakça

• Ahn, J.S., Harrington, W.J., Mylvaganam, R., Ayub, J., Pall, L.M., 1985. Danazol therapy for auto immune hemolytic anemia. Ann Intern Med. 102, 298-301.
• Atikson, J.P., Schreiber, A.D., Frank, M.M., 1973. Effects of corticosteroids and splenectomy on the immune clearance and destruction of eryt- hrocytes. J Clin Invest. 52, 1509.
• Balch, A., Mackin, A., 2007. Immunvermittelte haemolytische Anaemie beim Hund: Pathophysi- ologie, klinische Symptome und Diagnose. Tie- rarztl Prax. 35, 302-308.
• Bennett, D., Finnett, S.L., Nash A.S., Kirkham D., 1981. Primary autoimmune haemolytic anaemia in the dog. Vet Rec. 22, 150-153.
• Bizzarro, A., Valentini, G., Di Martino, G., Da- ponte, A., De Bellis, A., Iacono, G., 1987. Influ- ence of testosterone therapy on clinical and im- munological features of autoimmune diseases as- sociated with Klinefelter's syndrome. J Clin En- docr Metab. 64, 32–36.
• Bloom, J.C., Meunier, L.D., Thiem, P.A., Sellers, T.S., 1989. Use of danazol for treatment of corti- costeroid-resistant immune-mediated thrombocy- topenia in a dog. J Am Vet Med Assoc. 194, 76- 78.
• Burgess, K., Moore, A., Rand, W., Cotter, S.M., 2000. Treatment of immune-mediated hemolytic anemia in dogs with cyclophosphamide. J Vet In- tern Med. 14, 456-462.
• Cicardi, M., Bergamaschini, L., Tucci A., Agos- toni A., Tornaghi G., Coggi G., Colombi R., Viale G., 1983. Morphologic evaluation of the liver in hereditary angioedema patients on long- term treatment with androgen derivatives. J Al- lergy Clin Immun. 72, 294-298.
• Dourakis, S.P., Tolis, G., 1998. Sex hormonal preparations and the liver. Eur J Contracept Re- prod Health Care. 3, 7-16.
• Flores, G., Cunningham-Rundles, C., Newland A.C., Bussel J.B., 1993. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. Am J Hematol. 44, 237-242.
• Fries, L.F., Brickman, C.M., Frank M.M., 1983. Monocyte receptors for the Fc portion of IgG in- crease in number in autoimmune hemolytic ane- mia and other hemolytic states are decreased by glucocorticoid therapy. J Immunol. 131, 1240- 1245.
• Giger, U., 2000. Regenerative anemias caused by blood loss or hemolysis. In: S.J. Ettinger and E.C. Feldman (Eds): Textbook of Veterinary Internal Medicine, W.B. Saunders, Philadelphia, pp.1896- 1901.
• Hadley, S.P., Hoffmann W.E., Kuhlenschmidt M.S., Sanecki R.K., Dorner J.L., 1990. Effect of glucocorticoids on alkaline phosphatase, alanine aminotransferase, and gamma- glutamyltransferase in cultured dog hepatocytes. Enzyme. 43, 89-98.
• Hickson, R.C., Ball, K.L., Falduto M.T., 1989. Adverse effects of anabolic steroids. Med Toxicol Adverse Drug Exp. 4, 254-271.
• Holloway, S.A., Meyer, D.J., Mannella, C., 1990. Prednisolone and danazol for treatment of im- mune-mediated anemia, thrombocytopenia, and ineffective erythroid regeneration in a dog. J Am Vet Med Assoc. 197, 1045-1048.
• Jackson, M.L, Kruth, S.A., 1985. Immune- mediated Hemolytic Anemia and Thrombocyto- penia in the Dog: A retrospective study of 55 cases diagnosed from 1979 through 1983 at the Western College of Veterinary Medicine. Can Vet J. 26, 245-250.
• Kellerman, D.L., Bruyette, D.S., 1997. Intraven- ous human immunoglobulin for the treatment of immune-mediated hemolytic anemia in 13 dogs. J Vet Intern Med. 11, 327–332.
• Klag, A.R., Giger U., Shofer F.S., 1993. Idi- opathic immune-mediated hemolytic anemia in dogs: 42 cases (1986-1990). J Am Vet Med As- soc. 202: 783-788.
• Kopera, H., 1993. Side effects of anabolic stero- ids and contraindications. Wien Med Wo- chenschr. 143, 399-400.
• Lancia, A., Colella, F., Nicolella, U., Grandioso, P., Di Virgilio, D., 1991. Hepatic damage after danazol treatment. Ital J Gastroenterol. 23, 15- 16.
• Mason, N., Duval, D., Shofer, F.S., Giger, U., 2003. Cyclophosphamide exerts no beneficial ef- fect over prednisone alone in the initial treatment of acute immune-mediated hemolytic anemia in dogs: a randomized controlled clinical trial. J Vet Intern Med. 17, 206–212.
• Mccullough, S., 2003. Immune-mediated hemo- lytic anemia: understanding the nemesis. Vet Clin N Am-Small. 33, 1295-1315.
• McManus, P.M., Craig, L.E., 2001. Correlation between leukocytosis and necropsy findings in dogs with immune-mediated hemolytic anemia: 34 cases (1994-1999). J Am Vet Med Assoc. 218, 1308-1313.
• Miller, E., 1997. The use of danazol in the thera- py of immune-mediated disease of dogs. Semin Vet Med Surg (Small Anim). 12, 167–169.
• Miller, S.A., Hohenhaus A.E., Hale A.S., 2004. Case-control study of blood type, breed, sex, and bacteremia in dogs with immune-mediated hemo- lytic anemia. J Am Vet Med Assoc. 224, 232-235.
• Mills, J.N., 1997. Compensated immune me- diated haemolytic anaemia in a dog. Aust Vet J. 75: 177.
• Naoko, K., Tesuya, T., Kunihiko T., 1997. Tes- tosterone suppresses anti-DNA antibody produc- tion in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum. 40, 1703–1711.
• Nelson, R.W., Couto C.G., 1998. Immune hemo- lytic anemia In: Small Animal Internal Medicine C.G. Couto Mosby, St. Louis, pp.1162-1164, 1998.
• Olsen, N.J., Kovacks W.J., 1995. Case report: testosterone treatment of SLE in a patient with Klinefelter's syndrome. Am J Med Sci. 310, 158– 160.
• Petz, L.D., Garratty G., 1980. Management of autoimmune hemolytic anemias. In: Petz L.D., Garratty G. (Eds.), Acquired Immune Hemolytic Anemias. Churchill Livingstone, New York, pp. 392-440.
• Pugh, D.M., 1982. The hormones II: Anabolic steroids In: Brander G.C., Pugh D.M., Water R.J. (eds), Veterinary Applied Pharmacology and Therapeutics. Bailliere Tindall, London. pp. 202- 206.
• Reimer, M.E., Troy, G.C., Warnick, L.D., 1999. Immune-mediated hemolytic anemia: 70 cases (1988–1996). J Am Anım Hosp Assoc. 35, 384– 391.
• Rosse, W., Bussel, J., Ortel, T., 1997. Challenges in managing autoimmune disease. ASH Educa- tion Book. 25, 92-101.
• Solter, P.F., Hoffmann, W.E., Chambers M.D., Schaeffer D.J., Kuhlenschmidt M.S., 1994. He- patic total 3 alpha-hydroxy bile acids concentra- tion and enzyme activities in prednisone-treated dogs. Am J Vet Res. 55, 1086-1092.
• Switzer, J.W., Jain, N.C., 1981. Autoimmune hemolytic anemia in dogs and cats. Vet Clin N Am-Small 11, 405-4020.
• Vaden, S.L., 1997. Cyclosporine and tacrolimus. Semin Vet Med Surg (Small Anim). 12, 161–166.
• Van Vollenhoven, R.F., Morabito, L.M., Engle- man, E.G., Mcguire, J.L., 1998. Treatment of SLE with DHEA: 50 patients treated up to 12 months. J Rheumatol. 25, 285–289.
• Weinkle, T.K., Center, S.A., Randolph, J.F., Warner, K.L., Barr, S.C., Erb, H.N., 2005. Eval- uation of prognostic factors, survival rates, and treatment protocols for immune-mediated hemo- lytic anemia in dogs: 151 cases (1993-2002). J Am Vet Med Assoc. 226, 1869-1880.
• Yaginuma, T., Okamura, T., Takeuchi, T., Nishii, O., Fujimori, R., 1989. Preventive effect of tradi- tional herbal medicine, shosaiko-to, on danazol- induced hepatic damage. Int J Gynaecol Obstet. 29, 337-41.
• Yeo, S.W., Park, S.N., Chang, K.H., Chae S., Park Y.S., 2000. Effects of Testosterone in the Treatment of Immune-mediated Hearing Loss. Korean J Otolaryngol. 43, 1066-1072.
• Zofkova, I., Kancheva, R.L., Hampl, R., 1995. A decreasing CD4+/CD8+ ratio after one month of treatment with stanozol in postmenapausal wom- en. Steroids. 60, 430–433.